Gilead Sciences Inc. (GILD) Revenue-to-Profit Sankey Flow & SEC XBRL Financials
Gilead Sciences Inc. (GILD) receives a Roarable Rating of D (Sell) and flashes a Red SELL / AVOID warning (68/100 RQD Confidence). Our SEC filing scanner spotted paper earnings outpacing real operating cash flow (+227.5% (NI vs OCF)) while unpaid customer invoices grew—a classic sign to step aside until cash flow catches up.
How GILD Turns Every Dollar of Sales Into Real Bottom-Line Profit
Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory
| Fiscal Year | Revenue | Gross Margin | Op Margin | Net Profit | Free Cash Flow | ROIC % |
|---|---|---|---|---|---|---|
| FY 2025 | $29.44B | 78.8% | 34% | $8.51B | $9.46B | 20.7% |
| FY 2024 | $28.75B | 78.3% | 5.8% | $480.0M | $10.30B | 3.5% |
| FY 2023 | $27.12B | 44% | 28% | $5.67B | $6.79B | 8.8% |
Red-Light Warning Desk: How Pros Profit When Overhyped Stocks Crack (Featuring GILD)
- ✓Live walkthrough of GILD's RQD Radar, SEC cash-conversion gap & downside levels
- ✓3 asymmetric Bear/Hedge setups institutions use when 10-year yields stay elevated
- ✓Includes instant 24/7 email alert whenever any of your stocks flip to Red
GILD Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +2.4% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on GILD today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for GILD. Explore sector supply chains on /butterfly.
GILD Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDHow profitable is Gilead Sciences Inc. (GILD)?
In FY 2025 (10-K), GILD converted $29.4B of revenue into a 78.8% gross margin, 34% operating margin, and $9.5B in free cash flow (32.1% FCF margin).